Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
76.00
-0.20 (-0.26%)
Apr 28, 2026, 1:30 PM CST
3.12%
Market Cap 12.58B
Revenue (ttm) 1.73B
Net Income (ttm) 749.77M
Shares Out 165.53M
EPS (ttm) 4.83
PE Ratio 15.73
Forward PE n/a
Dividend 2.00 (2.62%)
Ex-Dividend Date n/a
Volume 482,574
Average Volume 550,662
Open 76.20
Previous Close 76.20
Day's Range 75.40 - 76.80
52-Week Range 67.30 - 154.00
Beta 0.85
RSI 52.65
Earnings Date May 14, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Employees 13
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

In 2025, Handa Pharmaceuticals's revenue was 1.73 billion, an increase of 108.17% compared to the previous year's 830.67 million. Earnings were 749.77 million, an increase of 58.60%.

Financial Statements

News

There is no news available yet.